Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues.
10.4093/jkd.2013.14.3.125
- Author:
Hyun Ji CHUN
1
;
Hyuk Sang KWON
Author Information
1. Department of Internal Medicine, Division of Endocrinology and Metabolism, The Catholic University of Korea, Seoul, Korea. drkwon@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Type 2 diabetes mellitus;
GLP-1 analogues;
Incretins
- MeSH:
Diabetes Mellitus, Type 2;
Glucagon;
Glucagon-Like Peptide 1;
Humans;
Hyperglycemia;
Incretins;
Peptides;
Venoms;
Liraglutide
- From:Journal of Korean Diabetes
2013;14(3):125-127
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes mellitus. These therapeutic agents could fill an important gap in glycemic control for patients with type 2 diabetes because the incretin response is blunted in type 2 diabetes mellitus. GLP-1 analogues can be classified as exendin-4 backbone (Exenatide, Exenatide LAR and Lixisenatide) and human GLP-1 backbone (Liraglutide, Taspoglutide and Albiglutide). Among these, Exenatide, Exenatide LAR and Liraglutide are currently available. This review will focus on the clinical efficacies of GLP-1 analogues in glycemic control for patients with diabetes.
